Testing effectiveness (Phase 2)Active Not RecruitingNCT03075696
What this trial is testing
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Who this might be right for
Non-Hodgkin's Lymphoma
Hoffmann-La Roche 940